JavaScript is disabled for your browser. Some features of this site may not work without it.
  • About K
  • Academics
  • Admission
  • Alumni Relations
  • Giving to K
  • News & Events
  • Student Life
  • HORNET HIVE
  • ATHLETICS
  • SITEMAP
  • WEBMAIL
    • Login
    View Item 
    •   CACHE Homepage
    • Academic Departments, Programs, and SIPs
    • Biology
    • Diebold Symposium Posters and Schedules
    • View Item
    •   CACHE Homepage
    • Academic Departments, Programs, and SIPs
    • Biology
    • Diebold Symposium Posters and Schedules
    • View Item

    The Role of the PI3K/AKT2 Pathway in Anti-Estrogen Resistant Breast Cancer

    Thumbnail
    View/Open
    poster presentation (193.4Kb)
    Date
    2004
    Author
    Busch, Stephanie M.
    Metadata
    Show full item record
    Abstract
    Breast cancer is one of the most common forms of cancer in women in the western world. Estrogen has been shown to play a key role in the development and progression of breast cancer with 2/3 of tumors expressing estrogen receptor-α (ERα). Under prolonged exposure to endogenous estrogens, breast tumors develop. Over the past two decades, Tamoxifen has been the most effective anti-estrogen therapy in the treatment of ERα-positive breast cancer (Osbourne et al., 1998). Unfortunately, patients eventually acquire resistance to Tamoxifen within four to eight years. Previous research has shown activation of PI3K/AKT2 and Ras/MAPK signaling pathways lead to tamoxifen resistance (Atanaskova, N et al., 2002). The purpose of this project is to establish the role of the PI3K/AKT2 pathway and its downstream signaling molecules, specifically mTOR, in anti-estrogen treatment. Inhibition of mTOR signaling by rapamycin was done to determine if p70 S6 Kinase and 4E-BP1 activation could be inhibited. In turn, cell cycle progression and tumor growth would, in theory, stop; therefore, tamoxifen resistance could be reversed in tumor cells that overexpress activated AKT2. Western blot analyses were conducted to visualize phosphorylated levels of 4E-BP1 and p70 S6 Kinase in EGFR/MCF-7 and MCF-7 cells. Overall, this research has implications for improving estrogen-mediated breast cancer treatment with Tamoxifen.
    URI
    http://hdl.handle.net/10920/4378
    Collections
    • Diebold Symposium Posters and Schedules [445]

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    DSpace software copyright © 2002-2022  DuraSpace
    DSpace Express is a service operated by 
    Atmire NV
    Logo

    Kalamazoo College
    1200 Academy Street
    Kalamazoo Michigan 49006-3295
    USA
    Info 269-337-7000
    Admission 1-800-253-3602

    About K
    Academics
    Admission
    Alumni Relations
    Giving to K
    News & Events
    Student Life
    Sitemap
    Map & Directions
    Contacts
    Directories
    Nondiscrimination Policy
    Consumer Information
    Official disclaimer
    Search this site


    Academic Calendars
    Apply
    Bookstore
    Crisis Response
    Employment
    Library
    Registrar
    DSpace Express is a service operated by 
    Atmire NV